Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3057% below fair value
$0.41−0.03 (-7.45%)
Close on Nov 20, 2026Market cap $121.65MP/E –Yield –
Invivyd free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Invivyd's free cash flow for the twelve months ending Jun 30, 2026 was -$109.66M. For fiscal 2025 it was -$58.29M. The highest annual figure on record is -$58.29M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.29M | – |
| FY2024 | Dec 31, 2024 | -$170.63M | – |
| FY2023 | Dec 31, 2023 | -$173.78M | – |
| FY2022 | Dec 31, 2022 | -$221.69M | – |
| FY2021 | Dec 31, 2021 | -$184.82M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$43.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$41.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$50.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$59.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.81M | – |
| Q4 FY2022 | Dec 31, 2022 | -$48.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$56.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$73.30M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.21M | – |
See a number that looks wrong?